MG1113

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation, GC Biopharma Corp

Conditions

Hemophilia

Phase 1

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

CompletedNCT03855696

Green Cross CorporationHemophilia

Start: 2019-01-21End: 2021-08-31Updated: 2021-10-26

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

CompletedNCT05493631

GC Biopharma CorpHemophilia

Start: 2022-08-24End: 2024-12-11Updated: 2025-11-24